CHI3L1 and neoplasm: In a proof-of-concept study published in 2021, the local delivery of a peptide-based inhibitor targeting CHI3L1/Gal-3 (Gal3BP mimetic peptide) into brain tumors demonstrated the ability to induce tumor regression in treated mice.